MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circulationaha.107.723866

Медицинская библиотека · Circulation · 2008

Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.

Roy Denis, Pratt Craig M, Torp-Pedersen Christian, Wyse D George, Toft Egon, Juul-Moller Steen, Nielsen Tonny, Rasmussen S Lind, Stiell Ian G, Coutu Benoit, Ip John H, Pritchett Edward L C, Camm A John, Atrial Arrhythmia Conversion Trial Investigators

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The present study assessed the efficacy and safety of vernakalant hydrochloride (RSD1235), a novel compound, for the conversion of atrial fibrillation (AF).

METHODS AND

RESULTS

Patients were randomized in a 2:1 ratio to receive vernakalant or placebo and were stratified by AF duration of 3 hours to 7 days (short duration) and 8 to 45 days (long duration). A first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes, followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if AF was not terminated. The primary end point was conversion of AF to sinus rhythm for at least 1 minute within 90 minutes of the start of drug infusion in the short-duration AF group. A total of 336 patients were randomized and received treatment (short duration, n=220; long duration, n=116). Of the 145 vernakalant patients, 75 (51.7%) in the short-duration AF group converted to sinus rhythm (median time, 11 minutes) compared with 3 of the 75 placebo patients (4.0%; P<0.001). Overall, in the short- and long-duration AF groups, 83 of the 221 vernakalant patients (37.6%) experienced termination of AF compared with 3 of the 115 placebo patients (2.6%; P<0.001). Transient dysgeusia and sneezing were the most common side effects in vernakalant-treated patients. Four vernakalant-related serious adverse events (hypotension [2 events], complete atrioventricular block, and cardiogenic shock) occurred in 3 patients.

CONCLUSIONS

Vernakalant demonstrated rapid conversion of short-duration AF and was well tolerated.

Для цитирования: Roy Denis, Pratt Craig M, Torp-Pedersen Christian, Wyse D George, Toft Egon, Juul-Moller Steen, Nielsen Tonny, Rasmussen S Lind, Stiell Ian G, Coutu Benoit, Ip John H, Pritchett Edward L C, Camm A John, Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.. Circulation. 2008. DOI: 10.1161/circulationaha.107.723866.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.